Tradestie Institutional Equity Comparison Engine

THOR vs HAE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HAE Overall Edge

HAE Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Haemonetics Corporation (HAE) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, THOR trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus HAE at 22.7x Forward P/E and 18.8% operating margin (+9.3% YoY). In options structure, THOR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against HAE sits in UNCLASSIFIED (2nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HAE
THOR N/M vs HAE 22.7x Fwd P/E
Growth & Margin Winner HAE
Op Margin N/A vs 18.8% ยท YoY N/A vs +9.3%
Momentum & Technical Winner HAE
1Y -1.4% vs +59.8% ยท 52W Pos 2% vs 85%
Options & Structure Winner HAE
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (2nd %ile IV)
THOR US Equity
THOR
Institutional Equity
$24.63
-1.7% 1D
Market Cap N/A
1M Return -3.92%
1Y Return -1.43%
Forward P/E N/M
Unified AI Score
44.5 / 100 HOLD
Tech 27.0 Fund 50.0 Flow 50.0 Mom 60.0
HAE NYSE
Haemonetics Corporation
Surgical & Medical Instruments & Apparatus
$120.16
-0.17% 1D
Market Cap $5.5B
1M Return +3.44%
1Y Return +59.81%
Forward P/E 22.7x
Unified AI Score
49.2 / 100 HOLD
Tech 40.0 Fund 38.0 Flow 50.0 Mom 21.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: THOR -1.43% HAE +59.81% Spread: +66.53 pp (HAE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
THOR TTM Op. Margin: N/A HAE TTM Op. Margin: 18.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on THOR vs HAE. Trailing 12-month operating profitability (THOR N/A vs HAE 18.8%) and valuation multiples (THOR N/M vs HAE 22.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: THOR (1) vs HAE (9)
Institutional Metric THOR HAE Criterion Row Winner
Market Capitalization Scale N/A $5.5B Larger Scale HAE
Trailing P/E Ratio Valuation N/M 53.3x Lower Multiple HAE
Forward P/E Ratio Valuation N/M 22.7x Lower Multiple HAE
Revenue Growth (YoY) Growth N/A +9.3% Higher Growth HAE
Operating Margin (TTM) Profitability N/A 18.8% Higher Margin HAE
Net Profit Margin Profitability N/A 7.5% Higher Margin HAE
Return on Equity (ROE) Capital Efficiency N/A 11.9% Higher ROE HAE
52-Week Range Position Momentum 2% ($25โ€“$29) 85% ($51โ€“$132) Stronger Trend HAE
Beta / 30D Volatility Risk Regime 0.46ฮฒ ยท 17% Vol 0.28ฮฒ ยท 33% Vol Lower Realized Risk THOR
Unified Institutional Score Composite Signal 44.5 / 100 (HOLD) 49.2 / 100 (HOLD) Higher Composite HAE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full THOR vs HAE Buy Guide
THOR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live THOR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HAE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live HAE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither THOR nor HAE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.